Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC lung cancer cooperative group

European Journal of Cancer

Volumn 33, Issue 11, 1997, Pages 1759-1766

  Van Zandwijk, N ^a   Groen, H J M ^b   Postmus, P E ^b,c   Burghouts, J Th W ^d   Ten Velde, G P M ^e   Ardizzoni, A ^f   Smith, I E ^g   Baas, P ^a   Sahmoud, T ^h   Kirkpatrick, A ^h   Dalesio, O ^a   Giaccone, G ^c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d JEROEN BOSCH HOSPITAL   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF GENOA   (Italy)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h EORTC DATA CENTER   (Belgium)

Author keywords

Interferon type II; Maintenance therapy; rIFN ; Small cell lung cancer

Indexed keywords

PARACETAMOL; RECOMBINANT GAMMA INTERFERON;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; FEVER; HEADACHE; HUMAN; LEUKOPENIA; LUNG CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON TYPE II; LUNG NEOPLASMS; MALE; PATIENT COMPLIANCE; SURVIVAL RATE;

EID: 0031424202     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00174-3     Document Type: Article

References (32)

1. Ihde DC, Pass HI, Glastein EJ. Small cell lung cancer. In De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1993, 723-758.
2. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992, 327, 1434-1441.
3. Van Zandwijk N. Are we moving towards continuous therapy in small cell lung cancer (SCLC)? Anticancer Res 1994, 14, 309-312.
4. Splinter TAW. EORTC 08825: induction versus induction plus maintenance chemotherapy in small cell lung cancer: definite evaluation. Proc Am Soc Clin Oncol 1988, 7, 202 (abstr 779.
5. Baron S, Tyring SK, Fleischmann WR, et al. The interferons. Mechanisms of action and clinical applications. JAMA 1991, 266, 1375-1383.
6. Quesada JR. Biologic therapy with Interferon-γ. In DeVita VT Jr, Hellman S, Rosenberg SA, ed. Biologic Therapy of Cancer. 2nd edn. Philadelphia, PA, Lippincott, 1995, 435-442.
7. Sreevalsan T. Biologic therapy with Interferon-α and β: preclinical studies. In DeVita VT Jr, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer. 2nd edn. Philadelphia, PA, Lippincott, 1995, 347-364.
8. Mattson K, Niiranen A, Holsti LR, et al. Low-dose α interferon as maintenance therapy for patients with small cell lung cancer. A follow-up report. Proc IASLC World Conference Interlaken. Lung Cancer 1988, 4, A173.
9. Twentyman PR, Workman P, Wright KA, et al. The effects of α and γ interferons on human lung cancer cells grown in vitro or as xenografts in nude mice. Br J Cancer 1985, 52, 21-29.
10. Blalock JE, Georgiades JA, Lanford MP, et al. Purified human immune gamma interferon has more potent anticellular activity than fibroblast or leukocyte interferon. Cell Immunol 1980, 49, 390-394.
11. Ball ED, Sorenson GD, Pettengill OS. Expression of myeloid and major histocompatibility antigens in small cell carcinoma of the lung cell lines by cytofluorography: modulation by gamma interferon. Cancer Res 1986, 46, 2335-2339.
12. Maluish AR, Urba WJ, Longo DL. The determination of an immunologically active dose of Interferon-gamma in patients with melanoma. J Clin Oncol 1988, 6, 434-445.
13. Jett JR, Su JQ, Maksymiuk AW. Phase III trial of recombinant interferon gamma (rIFN-γ) in complete responders (CR) with small cell lung cancer. Proc Am Soc Clin Oncol 1992, 11, 956.
14. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975, 31, 103-115.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50, 163-170.
17. Cox DR. Regression models and life tables. J R Stat Soc 1972, B34, 187-202.
18. Giaccone G, Dalesio, McVie JG, et al. Maintenance chemotherapy in small cell lung cancer: long-term results of a randomized trial. J Clin Oncol 1993, 11, 1230-1240.
19. Cullen M, Morgan D, Gregory W, et al. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: A randomized controlled trial. Cancer Chemother Pharmacol 1986, 17, 157-160.
20. Spiro SG, Souhami RL, Geddes DM, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1989, 59, 578-583.
21. Lebeau B, Chastang C, Capron F, et al. Small cell lung cancer: First analysis of a randomized clinical trial of 6 versus 12 chemotherapy cycles for complete responders. Eur Resp J 1992, 5, 286-290.
22. Ettinger DS, Finkelstein DM, Abeloff MD, et al. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive stage small cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 1990, 8, 230-240.
23. Jaffe HS, Herberman RB. Rationale for recombinant human interferon-gamma adjuvant immunotherapy for cancer. J Natl Cancer Inst 1988, 80, 616-618.
24. Jett JR, Maksymiuk AW, Su JQ, et al. Phase III trial of recombinant interferon gamma in complete responders with small cell lung cancer. J Clin Oncol 1994, 12, 2321-2326.
25. Mattson K, Niiranen A, Pyrhönen S, et al. Natural Interferon Alfa as maintenance therapy for small cell lung cancer. Eur J Cancer 1992, 28A, 1387-1391.
26. Kelly K, Crowley JJ, Bunn PA, et al. Role of recombinant interferon alfa-2a maintenance in patients with limited stage small cell lung cancer responding with concurrent chemoradiation: a Southwest Oncology Group Study. J Clin Oncol 1995, 13, 2924-2930.
27. Pujol JL, Gibney DJ, Su JQ, et al. Immune response induced in small cell lung cancer by maintenance therapy with Interferon-γ. J Natl Cancer Inst 1993, 85, 1844-1850.
28. Shaw EG, Denning RL, Creagan ET, et al. Pilot study of human recombinant interferon gamma and accelerated hyperfractioned thoracic radiation therapy in patients with unresectable stage IIIa/b non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1995, 31, 827-831.
29. De Mulder PHM, Oosterhof GON, Bouffioux C, et al. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. Br J Cancer 1995, 71, 371-375.
30. Bitran JD, Green M, Perry M, et al. A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. Am J Clin Oncol 1995, 18, 67-70.
31. Newman HFV, Bleehan NM, Galazka A, et al. Small cell lung carcinoma: a phase II evaluation of r-Interferon-γ. Cancer 1987, 60, 2938-2940.
32. Mulshine JL, Birrer M, Treston AM, et al. Growth factors and other targets for rational application as interventional agents. Adv Exp Med Biol 1992, 320, 81-88.